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Since prostate cancer is a heterogeneous disease both 
between patients and at the cellular level,  within 
patients, all population studies result in a median value 
for whatever parameter is being measured. Genome 
sequencing (and phenotyping)  have  contr ibuted 
massively to the resolution of inter-patient heterogeneity, 
EFòOJOHQBUJFOUHSPVQTBDDPSEJOHUPUSFBUNFOUSFTQPOTF
clinical grade and of course genomic fingerprint, but 
nevertheless statistical outliers persist. Is this because 
cancer is inherently heterogeneous, with several pathways 
capable of resulting in a final aggressively growing and 
invasive phenotype, or is it because sophisticated studies 
are still being carried out on heterogeneous mixtures 
of cells? 
In our recent study (1) as discussed by Giridhar et al. (2) 
in this journal, we adopted the same approach as we 
had many years ago for mRNA phenotypes (2), but now 
deliberately set out to test the hypothesis that the apparent 
non-concordance of the multiple miRNA studies in prostate 
cancer tissues was a direct result of heterogeneous cell 
mixtures. In fact little account was taken in earlier studies 
of e.g., stromal involvement, when extracting whole tissue 
biopsies, even after tissue microdissection. Did this mean 
that all previous genomic studies were wrong? I do not think 
TPFYDFQUUIBUUIFTJHOJòDBOUEBUBNBZCFIJEEFOXJUIJOB
NJYUVSFBOEBTTQFDJòDQIFOPUZQFTGPSEJGGFSFOUDFMMUZQFT
are determined, new software tools can presumably extract 
TJHOJòDBODF
We do agree with the authors of the commentary that 
the necessity to culture our cells for even a short time 
can skew the data, but since we are comparing different 
lesion types ALL of which are cultured, then we hope that 
culture artefacts will be in common and eliminated by our 
analysis. As we have shown previously (3), the expression 
levels of some mRNAs for secretory proteins in luminal 
cells are up to three orders of magnitude higher than in 
basal cellsimplying that even a 1% contamination will 
result in a ten-fold higher expression. The need for careful 
GSBDUJPOBUJPONFUIPEPMPHZsBOEUIFTBDSJòDFPGZJFME GPS
homogeneity cannot be overemphasised as mentioned 
further by Giridhar et al. (2). Ideally, fractionation should 
be simple and multifactorial (as we have demonstrated), 
but there is no golden rule, apart from a need to identify 
cell populations based on several independent factors, a 
lesson learned by haematologists long before epithelial 
biologists.
Such whole genome comparisons often result in a 
number of subsequent focussed analyses, and the Rane 
et al. study (1) is no exception. In a more recent paper (4) 
we described in more detail the analysis algorithm, which 
related miRNA expression to mRNA expression in the 
same cell populations. From this, we identified radiation 
response as a dominant gene ontology termand in 
particular the role of the miR-99a/100 family. Whereas miR-
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548c-3 showed striking effects on the stem-like phenotype 
of prostate epithelial cells, miR-99a/100 did notmRNA 
suppressed by miR-99a/100 did however contribute 
to radiation sensitivity in both established prostate 
cell lines and primary cells from human prostates (5). 
In the latter paper we showed that the most significant 
miR-99a/100 target genes encoded two SWI/SNF 
chromatin remodeling factors, SMARCA5 and SMARCD1, 
whose role in chromatin condensation has been defined 
previously. Manipulation of SMARC A5/D1 expression by 
means other than miRNA also affected radiation resistance, 
implying that part of stemness and radiation resistance is 
the presence of highly condensed chromatin. This agreed 
with our earlier studies, using HDAC inhibitors to 
unwind chromatin in stem-like cells (6), which resulted 
in greater radio-sensitivity. Finally, and unexpectedly, we 
showed that the chromatin state could be manipulated by 
glucocorticoid (GC) levels, via regulation of SMARCs. 
For example, administration of GC receptor inhibitors 
was able to promote radio-sensitivity in SC in a similar 
manner to HDAC inhibitors. This would imply that 
clinical application of GC response inhibitors such as 
Mifepristone in combination with standard radiotherapy 
protocols should improve outcomes. However,  as 
for many chemotherapies (e.g., docetaxel) when GC 
supplements are administered to improve patient 
XFMMCFJOH UIJTXPVMETFFNUPóZ JO UIF GBDFPG TUBOEBSE
clinical practice.
Lastly and perhaps with most significance for the 
future, the increasing applicability of single cell genomics 
and transcriptomics is set to transform the study of 
intratumoral cell heterogeneity. There have already 
been a number of examples, published with both solid 
and liquid (blood borne) tumour cells. The analysis has 
confirmed the expected heterogeneity, but here there is 
also a risk. If the single cell analysis is carried out as an 
exercise to confirm preconceptions from whole tissue 
analysis, then it is likely to ignore certain cell types as 
experimental artefact, particularly when these cells are 
in low abundance. There may indeed be several cell 
phenotypes in a cancer with stem-like propertiesbut is it 
the most common which is the most invasive or treatment 
SFTJTUBOU 5PEFUFDUUIFTUFNMJLFDFMMTXFIBWFEFòOFEJO
prostate cancer, would require the sequencing of >1,000 
cells from a random sample. Whilst this will be accessible 
using new barcoding technologies (7) to give an identity 
to each cell in a complex mixture, there is also a case for 
selection based not on phenotype, but rather on biological 
properties, prior to sequencing. In most experiments 
>99% of cells in a prostate tumour are non-tumorigenic 
in immuno-compromised mice. If you eliminate the stem-
like cells for example by blocking STAT3 signalling from 
an IL6 stimulus (8), then you prevent tumour induction. 
Unfortunately, current treatment strategies shrink existing 
cancers by treating the majority (non-tumour initiating) 
population. It probably does not matter what the genotype 
of the latter cells are, at 10× or even 100× sequencing 
coverage. To achieve longer lasting treatments both stem-
like and replicating bulk tumour cell populations must be 
destroyed.
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